

IN THE CLAIMS

1-25 (canceled)

26. (presently amended) A propellant free buccal spray composition for ~~transmucosal~~ administration of a pharmacologically active compound comprising:
an active compound in an amount of between 0.001 and 60 percent by weight of the total composition selected from the group consisting of biologically active peptides, central nervous system acting amines, sulfonyl ureas, antibiotics, antifungals, sleep inducers, antiasthmatics, antiemetics, antivirals, histamine H-2 receptor antagonists, barbiturates, prostoglandins, and bronchial dilators selected from terbutaline and theophylline; and
a polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is adapted for transmucosal absorption of the active compound through the oral mucosa when administered to a mammal to provide the active compound in the systemic circulatory system of the mammal.

27. (previously added) The composition of claim 26, further comprising a flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.

28. (previously added) The composition of claim 27, wherein the polar solvent is present in an amount between 37 and 98 percent by weight of the total composition, the active compound is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

29. (previously added) The composition of claim 28, wherein the polar solvent is present in an amount between 59 and 97 percent by weight of the total composition, the active compound is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

30. (previously added) The composition of claim 26, wherein the polar solvent is selected from the group consisting of polyethylene glycols having a molecular weight

between 400 and 1000, C₂ to C₈ mono- and poly-alcohols, and C₇ to C₁₈ alcohols of linear or branched configuration.

31. (previously added) The composition of claim 26, wherein the polar solvent comprises aqueous polyethylene glycol.

32. (previously added) The composition of claim 26, wherein the polar solvent comprises aqueous ethanol.

33. (previously added) The composition of claim 26, wherein the active compound is selected from the group consisting of cyclosporin, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valerin, and pharmaceutically acceptable salts thereof.

34. (previously added) The composition of claim 27, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

35. (previously added) The composition of claim 27, wherein the polar solvent is present in an amount between 75 and 85 percent by weight of the total composition, the active compound is cyclosporin present in an amount between 15 and 25 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.

36. (previously added) The composition of claim 27, wherein the polar solvent is present in an amount between 19 and 90 percent by weight of the total composition, the active compound is ondansetron hydrochloride present in an amount between 2.5 and 15 percent by weight of the total composition, and the flavoring agent is present in an amount between 1 and 10 percent by weight of the total composition.

37. (previously added) A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of said mammal with the composition of claim 26.

[Handwritten mark]

38. (previously added) The method of claim 37, wherein the amount of the spray is predetermined.

39-52 (canceled)

53. (presently amended) A propellant free buccal spray composition for ~~transmucosal~~ administration of a pharmacologically active compound comprising:

[Handwritten mark]

an active compound in an amount between 0.005 and 55 percent by weight of the total composition selected from the group consisting of biologically active peptides, central nervous system acting amines, sulfonyl ureas, antibiotics, antifungals, sleep inducers, antiasthmatics, antiemetics, antivirals, histamine H-2 receptor antagonists, barbiturates, prostoglandins, and bronchial dilators selected from terbutaline and theophyline; and

a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is adapted for transmucosal absorption of the active compound through the oral mucosa when administered to a mammal to provide the active compound in the systemic circulatory system of the mammal.

54. (previously added) The composition of claim 53, further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.

55. (previously added) The composition of claim 54, wherein the non-polar solvent is present in an amount between 69 and 99 percent by weight of the total composition, the active compound is clozepine in an amount from between 0.5 and 30 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.

56. (previously added) The composition of claim 53, wherein the active compound is selected from the group consisting of cyclosporin, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost thromethamine, valerin, and pharmaceutically acceptable salts thereof.

57. (previously added) The composition of claim 54, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.

58. (previously added) The composition of claim 53, wherein the solvent is selected from the group consisting of (C₂-C₂₄) fatty acid (C₂-C₆) esters, C₇-C₁₈ hydrocarbons of linear or branched configuration, C₂-C₆ alkanoyl esters, and triglycerides of C₂-C₆ carboxylic acids.

59. (previously added) The composition of claim 53, wherein the solvent is ~~is miglyol~~ comprises one or more fatty acid esters.

60. (previously added) A method of administering a pharmacologically active compound to a mammal comprising spraying the oral mucosa of said mammal with the composition of claim 53.

61. (previously added) The method of claim 60, wherein the amount of the spray is predetermined.

62-78 (canceled)

79. (New) A buccal spray composition for ~~transmucosal~~ administration of a pharmacologically active compound comprising:

an active compound in an amount between 0.005 and 55 percent by weight of the total composition selected from the group consisting of antihistamines, alkaloids, hormones, benzodiazepines, and narcotic analgesics;

a non-polar solvent in an amount between 30 and 99 percent by weight of the total composition,

wherein said composition is adapted for transmucosal absorption of the active compound through the oral mucosa when administered to a mammal to provide the active compound in the systemic circulatory system of the mammal.